Hybrid ligand directed to activation of cytotoxic effector T lym

Details Hybrid ligand directed to activation of cytotoxic effector T lym Hybrid ligand directed to activation of cytotoxic effector T lym

1985-08-02

1992-01-07

Moskow, Margaret

Drug, bio-affecting and body treating compositions

Lymphokine

530391, A61K 3944, C07K 1506

Patent

active

050789988

ABSTRACT:
A hybrid ligand molecular composed of an antibody combining site that binds to a T cell receptor complex structure and is capable of activating cytotoxic T lymphocytes linked to a target cell-specific antibody is disclosed. This ligand molecule can bind to an antigen on the surface of a target cell and to cytotoxic effector T lymphocyte cell receptor complex structures. A composition and a method for killing tumor cells with the hybrid ligand molecule of this invention are provided.

REFERENCES:
Marty Ie., Immunology Today, vol. 5, No. 9, (254-255, (1984).
Staerz, V. D. et al., Nature, 314:628-631, (Apr. 18, 1985).
Staerz, V. D. et al., Journal of Immunology, 134(6): 3994-4000, (Jun. 1985).
Karpovsky, B. et al., J Exper. Med., 160:1686-1701, (12-1984).
"Use of Anti-Receptor Antibodies to Focus T-Cell Activity", published in Immunology Today, 7:241-245, (1986), co-authored by Drs. Bevan and Staerz.

Affiliated with

Also associated with

Rating

Hybrid ligand directed to activation of cytotoxic effector T lym does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid ligand directed to activation of cytotoxic effector T lym, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid ligand directed to activation of cytotoxic effector T lym will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-820583